IndieBio

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to innovate crop development for future agricultural needs. Utilizing AI-assisted plant breeding, Avalo ensures that all its products are non-GMO and promote natural biodiversity. The company's core technology is a discovery engine that efficiently identifies the genetic foundations of complex traits, significantly shortening the time and reducing the costs associated with developing new crops. By focusing on traits such as drought tolerance, water-use efficiency, and nutrient density, Avalo's platform enhances crop evolution to adapt to changing climate conditions. This approach allows researchers to improve crop quality while providing diagnostic forecasting and gene discovery capabilities, ultimately advancing agricultural practices.

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

TippingPoint Biosciences is focused on developing therapeutics that address diseases linked to defects in DNA packaging, including various cancers and neurodegenerative disorders. Utilizing a drug discovery platform, the company aims to identify innovative treatments that specifically target unique genome packaging states associated with these diseases. This approach not only facilitates the treatment of cancers but also supports the development of stem cell therapies by addressing the underlying issues of dysfunctional genome packaging. Through its efforts, TippingPoint Biosciences seeks to advance medical care and improve patient outcomes in complex genetic conditions.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Wayfinder Biosciences is a biotechnology company based in Seattle, WA, focused on developing orally available small molecule drugs that target RNA to address key disease areas such as oncology and neurodegenerative disorders. Established in 2021, the company employs a proprietary platform that integrates advanced screening technologies and computational methods to efficiently discover potent and selective RNA-targeting molecules. By leveraging high-throughput screening combined with machine learning and unique datasets, Wayfinder aims to enable the development of drugs for traditionally inaccessible targets, thus addressing significant unmet medical needs in genetic diseases, cancer, and other conditions.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

AnimalBiome specializes in personalized nutrition services focused on enhancing the gut health of dogs and cats through the science of the microbiome. The company offers microbiome tests that analyze the gut microbiome of individual pets, providing tailored nutrition recommendations based on the results. Additionally, AnimalBiome produces restorative supplements designed to introduce beneficial microbes sourced from healthy pets, helping to address microbiome imbalances. Through advanced diagnostics, including DNA sequencing, the company enables pet owners to gain insights into their pets' gut health, ultimately promoting a healthier and happier life for their animals.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Indee Labs specializes in developing innovative hardware for gene delivery, focusing on a non-viral intracellular delivery system. This technology facilitates the efficient development and scalable manufacture of gene-modified cell therapies, including chimeric antigen receptor T cells. By employing microfluidic vortex shedding, the system enables the gentle delivery of constructs such as nucleic acids, proteins, and gene-editing complexes to a variety of cell types, ensuring maximum recovery of viable, modified cells with minimal disruption. Indee Labs collaborates with the Australian National Fabrication Facility and has established its presence with offices in Sydney and lab space at Bonneville Labs in Berkeley. The company is recognized for its contributions to the field, having affiliations with NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Wayfinder Biosciences is a biotechnology company based in Seattle, WA, focused on developing orally available small molecule drugs that target RNA to address key disease areas such as oncology and neurodegenerative disorders. Established in 2021, the company employs a proprietary platform that integrates advanced screening technologies and computational methods to efficiently discover potent and selective RNA-targeting molecules. By leveraging high-throughput screening combined with machine learning and unique datasets, Wayfinder aims to enable the development of drugs for traditionally inaccessible targets, thus addressing significant unmet medical needs in genetic diseases, cancer, and other conditions.

Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to innovate crop development for future agricultural needs. Utilizing AI-assisted plant breeding, Avalo ensures that all its products are non-GMO and promote natural biodiversity. The company's core technology is a discovery engine that efficiently identifies the genetic foundations of complex traits, significantly shortening the time and reducing the costs associated with developing new crops. By focusing on traits such as drought tolerance, water-use efficiency, and nutrient density, Avalo's platform enhances crop evolution to adapt to changing climate conditions. This approach allows researchers to improve crop quality while providing diagnostic forecasting and gene discovery capabilities, ultimately advancing agricultural practices.

Basin Genomics is combining scientific backgrounds in genomics and oncology with startup expertise to translate genetic discoveries into advances in personalized clinical care as it strives to develop technology that will decrease the rates of cervical cancer globally.

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

Microgenesis is a biotechnology company focused on improving fertility and pregnancy health through innovative diagnostic and treatment solutions. It offers a non-invasive fertility test that identifies subclinical inflammation affecting ovarian function and implantation, particularly beneficial for women who have experienced multiple IVF failures. The company's personalized nutritional supplementation aims to restore fertility potential in women, utilizing all-natural and drug-free methods. Operating out of a CLIA-certified lab in Oakland, Microgenesis is expanding its services to obstetricians and gynecologists, as well as direct-to-consumer markets. In addition to its fertility test, the company provides tools to analyze microbiota imbalances linked to infertility and immunological issues, thus addressing complex reproductive health cases comprehensively.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Biomage is a company that focuses on single-cell analysis to advance life sciences research. It has developed a platform that transforms extensive single-cell sequencing data into meaningful biological insights, enabling researchers to conduct in-depth analyses with ease. This platform specifically caters to the needs of research biologists, facilitating the analysis of single-cell RNA sequencing. By streamlining the data interpretation process, Biomage enhances the potential for drug target discovery while significantly reducing costs. The company aims to empower scientists in both academia and industry, promoting the broader use of advanced sequencing technologies in various biological disciplines.

Biomage is a company that focuses on single-cell analysis to advance life sciences research. It has developed a platform that transforms extensive single-cell sequencing data into meaningful biological insights, enabling researchers to conduct in-depth analyses with ease. This platform specifically caters to the needs of research biologists, facilitating the analysis of single-cell RNA sequencing. By streamlining the data interpretation process, Biomage enhances the potential for drug target discovery while significantly reducing costs. The company aims to empower scientists in both academia and industry, promoting the broader use of advanced sequencing technologies in various biological disciplines.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Biomage is a company that focuses on single-cell analysis to advance life sciences research. It has developed a platform that transforms extensive single-cell sequencing data into meaningful biological insights, enabling researchers to conduct in-depth analyses with ease. This platform specifically caters to the needs of research biologists, facilitating the analysis of single-cell RNA sequencing. By streamlining the data interpretation process, Biomage enhances the potential for drug target discovery while significantly reducing costs. The company aims to empower scientists in both academia and industry, promoting the broader use of advanced sequencing technologies in various biological disciplines.

Circularis Biotechnologies, Inc. is a biotechnology company focused on developing innovative methods to regulate gene expression, aiming to enhance the production yields of biotherapeutics. Founded in 2014 and based in Oakland, California, the company offers a range of products and services, including RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. Additionally, Circularis provides services such as RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. Through its technology, Circularis Biotechnologies seeks to advance the capabilities of biotherapeutic production in the industry.

Catalog is a developer of a data conversion and storage platform used to offer the next generation of digital data archives and computation. Its platform facilitates the encoding of data and information into DNA format and makes it economically attractive to use DNA as the major medium for long-term archival of data that enables customers to store digital information in DNA molecules. It brings cutting-edge synthetic biology technologies to the world of information storage and computation. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Pando Nutrition, Inc. is an animal microbiome company focused on developing innovative probiotics to support antibiotic-free livestock production. Based in San Francisco, California, and incorporated in 2017, the company aims to address the antibiotic resistance crisis by utilizing genetically engineered probiotics that enhance livestock health and performance without relying on medically significant drugs. Pando Nutrition offers Panbiotics, a platform designed to identify and control methane emissions, thereby improving feed efficiency and profitability in livestock. Additionally, the company is engaged in the development of solutions for poultry pathogens, such as Coccidiosis. By leveraging advanced biotechnology, Pando Nutrition creates yeast-based systems for animal feed that not only boost animal health and immunity but also enable the production of essential nutrients, contributing to a sustainable and efficient food supply chain.

Ravata is enabling production scale embryo engineering.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Serenity Bioworks is focused on developing innovative therapies that address significant gaps in healthcare, particularly in the fields of gene therapy and targeted protein degradation. The company creates antibody mimetics aimed at enhancing the process of targeted protein degradation by integrating advanced display techniques with computational methods to optimize discovery. Additionally, Serenity is working on gene therapies designed to treat conditions such as hemophilia, inherited retinal diseases, and neurodegenerative diseases. These therapies are designed to improve patient outcomes by enabling healthcare providers to enhance the efficacy and safety profiles of treatments, ultimately leading to safer and more durable solutions for patients.

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

Osiris Bio

Serenity Bioworks is focused on developing innovative therapies that address significant gaps in healthcare, particularly in the fields of gene therapy and targeted protein degradation. The company creates antibody mimetics aimed at enhancing the process of targeted protein degradation by integrating advanced display techniques with computational methods to optimize discovery. Additionally, Serenity is working on gene therapies designed to treat conditions such as hemophilia, inherited retinal diseases, and neurodegenerative diseases. These therapies are designed to improve patient outcomes by enabling healthcare providers to enhance the efficacy and safety profiles of treatments, ultimately leading to safer and more durable solutions for patients.

Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completely personalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes.

Dahlia Biosciences is a biotechnology company based in California, founded in 2011. It focuses on DNA analysis and diagnostics, specializing in single-cell RNA analysis tools that are applicable for both research and diagnostic purposes. The company develops RNA detection tools utilizing CRISPR-Cas9 technology, which allows for the detection of multiple DNA and RNA biomarkers directly within cells and tissues. This innovative approach enables scientists to study and isolate cells with high precision and resolution, facilitating advancements in precision medicine research.

Onconetics Pharmaceuticals, Inc. is a biotechnology company based in Mill Valley, California, focused on developing personalized gene therapies for cancer and other genetic disorders. Established in 2016, the company employs a unique therapeutic platform that utilizes a genetic switch to activate an apoptotic inducer, selectively targeting and eliminating tumor cells while preserving healthy tissue. This innovative approach combines established gene therapy techniques with advanced research to create treatments that aim to improve patient outcomes by reducing the invasiveness and side effects associated with traditional therapies. Onconetics seeks to advance the field of personalized medicine by offering simpler, versatile therapies that prioritize patient safety and quality of life.

Catalog is a developer of a data conversion and storage platform used to offer the next generation of digital data archives and computation. Its platform facilitates the encoding of data and information into DNA format and makes it economically attractive to use DNA as the major medium for long-term archival of data that enables customers to store digital information in DNA molecules. It brings cutting-edge synthetic biology technologies to the world of information storage and computation. The company was founded in 2016 and is headquartered in Boston, Massachusetts.

Indee Labs specializes in developing innovative hardware for gene delivery, focusing on a non-viral intracellular delivery system. This technology facilitates the efficient development and scalable manufacture of gene-modified cell therapies, including chimeric antigen receptor T cells. By employing microfluidic vortex shedding, the system enables the gentle delivery of constructs such as nucleic acids, proteins, and gene-editing complexes to a variety of cell types, ensuring maximum recovery of viable, modified cells with minimal disruption. Indee Labs collaborates with the Australian National Fabrication Facility and has established its presence with offices in Sydney and lab space at Bonneville Labs in Berkeley. The company is recognized for its contributions to the field, having affiliations with NSW Health, IndieBio, Y Combinator, and MBC Biolabs.

Stelvio Therapeutics is a biopharmaceutical company focused on developing innovative treatments for incurable cancers and neurodegenerative diseases. Founded in 2017 and based in San Diego, California, the company utilizes a machine vision and learning platform to drive diseased stem cells toward non-diseased states. Its proprietary technology, known as microscopic imaging of epigenetic landscapes (MIEL), facilitates the discovery of small molecules that can induce epigenetic changes, allowing for the differentiation or reversal of cancerous cells into benign types, which holds potential for curative outcomes. Additionally, Stelvio is pursuing a personalized approach to glioblastoma treatment, leveraging its team's expertise in scientific innovation and clinical management to advance novel drug therapies and precision medicine diagnostics.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Headquartered in South San Francisco, Jungla is a biotechnology company delivering robust and scalable results for clinical genetic and genomic testing. To achieve this, Jungla develops and combines advances in functional genomics, computational biophysics, and computer science to proactively inform on the risk of variants in our genome. Jungla aims to empower clinical genetic testing with quantitative, model-driven guidance to complement and enhance observational data. Whereas existing solutions routinely used in the market have demonstrably poor accuracies, Jungla delivers robust, scalable, and auditable support with dramatically higher accuracies and increasingly mechanistic cellular and biophysical insights. We are supported by leading technology and healthcare investors.

Ravata is enabling production scale embryo engineering.

Ravata is enabling production scale embryo engineering.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Genome Surveillance is advancing DNA sequencing technology to address current limitations in speed and accuracy. By utilizing innovative scaffold sequencing methods, the company enables medical researchers to obtain precise genomic information, facilitating genome reconstruction, structure variation discovery, and the development of molecular markers for agricultural research. This technology significantly reduces the computational burden associated with traditional sequencing methods, making the process ten times faster and more reliable while lowering costs substantially. As a result, Genome Surveillance is positioned to meet the increasing demand for efficient and accurate DNA sequencing, thereby contributing to advancements in medical and agricultural genomics.

Amino Labs is a biotechnology company that aims to make genetic engineering accessible to everyone. It works to enable the next industrial revolution of personalized manufacturing using biology and help solve the world's biggest problem from fuel to food to medicine. Driven by ground-breaking technology and UX, Amino Labs' easy-to-use kits are giving rise to the next 99 million bioengineers, from the ages of 8 and up. The company was founded in 2015 and is based in Lethbridge, Canada.

Genesis DNA is focused on revolutionizing gene synthesis, which involves transforming digital sequences into physical DNA. Utilizing a proprietary method, the company addresses the challenges of cost, turnaround time, and limitations associated with traditional synthesis techniques. Founded by a group of students from Stanford and MIT, Genesis DNA aims to provide researchers with fast, affordable, and secure access to any DNA sequence they require. The company's innovative approach reflects a vision that the future of technological advancement will be rooted in biological applications.

At DtoR they have developed the PCR of gene expression—a disruptive technology that will revolutionize the tools used to “tune” protein production in any organism. In one step, and for any cell type, they can identify all of the switches regulating expression of the genome, as well as how active they are. They can also rapidly evolve or synthesize new switches to adapt to any application. Applications developed using their platform will lead to improved product yields in bioreactors, engineered specialty crops, optimized cancer therapeutics, and much more. The possibilities are limited only by their partners' imaginations.

Girihlet Inc. is a genetic-sequencing company based in Oakland, California, established in 2012. The company specializes in providing rapid and accurate deep sequencing services, focusing on non-canonical genomics solutions. Girihlet has developed patented technologies for profiling T cell receptors and sequencing mitochondrial DNA, utilizing novel, bias-free methods to analyze these genetic components. This approach aims to harness the potential of T cell receptors and mtDNA as biomarkers for diagnostics across various disorders, particularly those driven by T-cell-related autoimmune conditions. By employing deep sequencing and machine learning, Girihlet seeks to decode individual immune responses and guide effective therapeutic strategies, thereby contributing significantly to both clinical applications and advanced research in immunology.

Arcturus BioCloud is a virtual bio-foundry for rapid prototyping microorganisms using genetic engineering. They’ve simplified the outsourcing of experiments on and yeast by seamlessly integrating genetic engineering technologies into a user-friendly platform that covers the whole genetic engineering cycle. Users can upload on Arcturus BioCloud their biological design, and they will build and test it for them. This way, helping organisations accelerate their process of developing innovative products. For that, they already have in place partnerships with Synbiota and ZymoResearch that provide us with advance technologies. In the following months, they will be adding new partnerships to extend their service portfolio. Their mission is to make more accessible these technologies so that scientists from all around the world can work with the best tools, regardless of their geographical limitations. They also have a great team; they met at Singularity University, and they cover all the domains required for executing the mission. Biotechnology is one of the fastest-growing markets, mainly because of the exponential price reduction of Synthesizing and Sequencing, which is beating Moore’s Law. As the prices decrease, more people will start to create innovations and companies. They see this future very close, and that is why they’ve started providing these technologies that in the following years will be 100x cheaper.

Ranomics focuses on providing individuals with health risk predictions according to their genetic data. Ranomics offers RanomicsDB and Ranomics API. RanomicsDB is a query interface with VCF support. Ranomics API is a developer-friendly API that enables variant interpretation software companies to integrate data to enhance their existing pipeline. Ranomics was founded in 2015 by Leo Wan and Cathy Tie. And it is based in San Francisco, California.